-DOCSTART- -X- O
It -X- _ O
is -X- _ O
now -X- _ O
accepted -X- _ O
that -X- _ O
an -X- _ O
overwhelming -X- _ O
inflammatory -X- _ O
response -X- _ O
is -X- _ O
the -X- _ O
cause -X- _ O
of -X- _ O
human -X- _ O
deaths -X- _ O
from -X- _ O
avian -X- _ B-Patient
H5N1 -X- _ I-Patient
influenza -X- _ I-Patient
infection. -X- _ I-Patient
With -X- _ O
this -X- _ O
in -X- _ O
mind -X- _ O
we -X- _ O
sought -X- _ O
to -X- _ O
examine -X- _ O
the -X- _ O
literature -X- _ O
for -X- _ O
examples -X- _ O
of -X- _ O
complementary -X- _ B-Intervention
and -X- _ I-Intervention
alternative -X- _ I-Intervention
medicines -X- _ I-Intervention
that -X- _ I-Intervention
reduce -X- _ I-Intervention
inflammation -X- _ I-Intervention
, -X- _ O
and -X- _ O
to -X- _ O
place -X- _ O
the -X- _ O
results -X- _ O
of -X- _ O
this -X- _ O
search -X- _ O
in -X- _ O
the -X- _ O
context -X- _ O
of -X- _ O
our -X- _ O
own -X- _ O
work -X- _ O
in -X- _ O
a -X- _ O
mouse -X- _ B-Patient
model -X- _ I-Patient
of -X- _ I-Patient
influenza -X- _ I-Patient
disease -X- _ I-Patient
, -X- _ O
using -X- _ O
a -X- _ O
pharmaceutical -X- _ O
agent -X- _ O
with -X- _ O
anti-inflammatory -X- _ O
properties. -X- _ O
Two -X- _ O
Chinese -X- _ B-Intervention
herbs -X- _ I-Intervention
, -X- _ I-Intervention
Angelica -X- _ I-Intervention
sinensis -X- _ I-Intervention
( -X- _ I-Intervention
Dang -X- _ I-Intervention
Gui -X- _ I-Intervention
) -X- _ I-Intervention
and -X- _ I-Intervention
Salvia -X- _ I-Intervention
miltiorrhiza -X- _ I-Intervention
( -X- _ I-Intervention
Danshen -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ O
have -X- _ O
been -X- _ O
recently -X- _ O
shown -X- _ B-Outcome
to -X- _ I-Outcome
protect -X- _ I-Outcome
mice -X- _ I-Outcome
during -X- _ I-Outcome
lethal -X- _ I-Outcome
experimental -X- _ I-Outcome
sepsis -X- _ I-Outcome
via -X- _ I-Outcome
inhibition -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
novel -X- _ I-Outcome
inflammatory -X- _ I-Outcome
cytokine -X- _ I-Outcome
High -X- _ I-Outcome
Mobility -X- _ I-Outcome
Group -X- _ I-Outcome
Box -X- _ I-Outcome
1 -X- _ I-Outcome
protein -X- _ I-Outcome
( -X- _ I-Outcome
HMGB1 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ O
Biochanin -X- _ B-Intervention
A -X- _ I-Intervention
, -X- _ O
a -X- _ O
ligand -X- _ O
of -X- _ O
the -X- _ O
peroxisome -X- _ O
proliferator -X- _ O
activated -X- _ O
receptors -X- _ O
( -X- _ O
PPAR -X- _ O
) -X- _ O
alpha -X- _ O
and -X- _ O
gamma -X- _ O
and -X- _ O
the -X- _ O
active -X- _ O
isoflavone -X- _ O
in -X- _ O
Trifolium -X- _ O
pratense -X- _ O
( -X- _ O
red -X- _ O
clover -X- _ O
) -X- _ O
, -X- _ O
has -X- _ B-Outcome
anti- -X- _ I-Outcome
inflammatory -X- _ I-Outcome
properties -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
thus -X- _ I-Outcome
could -X- _ I-Outcome
be -X- _ I-Outcome
used -X- _ I-Outcome
as -X- _ I-Outcome
an -X- _ I-Outcome
influenza -X- _ I-Outcome
treatment. -X- _ I-Outcome
This -X- _ O
is -X- _ O
of -X- _ O
great -X- _ O
interest -X- _ O
since -X- _ O
we -X- _ O
have -X- _ O
recently -X- _ O
shown -X- _ O
that -X- _ O
gemfibrozil -X- _ B-Intervention
, -X- _ O
a -X- _ O
drug -X- _ O
used -X- _ O
to -X- _ O
treat -X- _ O
hyperlipidemia -X- _ O
in -X- _ O
humans -X- _ O
and -X- _ O
a -X- _ O
synthetic -X- _ O
ligand -X- _ O
of -X- _ O
PPAR -X- _ O
alpha -X- _ O
, -X- _ O
significantly -X- _ B-Outcome
reduces -X- _ I-Outcome
the -X- _ I-Outcome
mortality -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
influenza -X- _ I-Outcome
infections -X- _ I-Outcome
in -X- _ I-Outcome
mice. -X- _ I-Outcome
The -X- _ O
inflammation-modulating -X- _ O
abilities -X- _ O
of -X- _ O
these -X- _ O
natural -X- _ O
agents -X- _ O
should -X- _ O
be -X- _ O
considered -X- _ O
in -X- _ O
light -X- _ O
of -X- _ O
what -X- _ O
is -X- _ O
now -X- _ O
known -X- _ O
about -X- _ O
the -X- _ O
mechanisms -X- _ O
of -X- _ O
fatal -X- _ B-Patient
influenza -X- _ I-Patient
, -X- _ O
and -X- _ O
tested -X- _ O
as -X- _ O
potential -X- _ O
candidates -X- _ O
for -X- _ O
influenza -X- _ O
treatments -X- _ O
in -X- _ O
their -X- _ O
own -X- _ O
right -X- _ O
, -X- _ O
or -X- _ O
as -X- _ O
adjunct -X- _ O
treatments -X- _ O
to -X- _ O
antivirals -X- _ O
. -X- _ O

